Current status of genetic modification of T cells for cancer treatment

G. Dotti, Helen E. Heslop

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Clinical studies of adoptive immunotherapy with T cells have shown activity directed at hematologic and solid malignancies and viral infections. Genetic modification of infused T cells offers the prospect of improving such therapies and has already been used to track infused T cells, insert suicide genes and redirect the immune response towards specific Ag. Pre-clinical studies are evaluating novel approaches to genetically modify T cells to confer resistance to tumor evasion mechanisms. There is also increasing interest in developing suicide gene strategies as a failsafe mechanism to eradicate genetically modified cells should adverse effects occur.

Original languageEnglish (US)
Pages (from-to)262-272
Number of pages11
Issue number3
StatePublished - 2005


  • Cytotoxic T cells
  • Immunotherapy

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology


Dive into the research topics of 'Current status of genetic modification of T cells for cancer treatment'. Together they form a unique fingerprint.

Cite this